Clinical trials
Researchers have reported encouraging results from a new feasibility study looking to find a potential treatment for Long Covid.
The £1.2m ERASE – long COVID trial, managed by the University of Plymouth's Peninsula Clinical Trials Unit (PenCTU) and led by the University of Derby, explored whether an antiviral drug delivered intravenously could be used to treat people with Long Covid.
The study found that delivering a five-day intravenous treatment and carrying out the assessments needed to evaluate it in people with Long Covid was safe and feasible.
While the project was established to test the feasibility of using intravenous medications, researchers reported a number of encouraging changes in exploratory outcome measures, with most participants reporting reductions in fatigue, improved quality of life and increased walking distance in a timed walking test.
Now the research team is calling for a larger randomised controlled trial to establish whether the antiviral treatment is effective for people with Long Covid.
The findings have been outlined in a study published in the Oxford Open Immunology journal, and included: 
  • The five-day intravenous treatment regimen could be successfully delivered;
  • Participants were able to complete the clinical assessments required for the research;
  • The study generated important information needed to plan a larger randomised controlled trial.

The successful completion of ERASE demonstrates why feasibility studies are so important.

Before investing in a large-scale efficacy trial, we need confidence that recruitment, treatment delivery, data collection and participant follow-up can all be achieved. The findings from ERASE show that these key elements are workable in people living with Long Covid and provide the foundations for a future definitive trial.

Victoria AllgarProfessor Victoria Allgar
Professor of Medical Statistics and Director of PenCTU

More than two million people in the UK have been estimated to be living with Long Covid. Symptoms can vary considerably and include extreme fatigue, breathlessness, palpitations and brain fog.

These findings are an important step forward in our research into potential treatments for Long Covid. We have shown that it is possible to deliver this intravenous antiviral treatment and undertake the assessments needed to evaluate it in people with Long Covid. We also saw encouraging changes in measures including fatigue, functional capacity, quality of life and commonly reported symptoms. While ERASE was not designed to tell us whether the treatment caused those changes or whether the treatment works, the findings give us a strong rationale for carrying out a larger randomised controlled trial that will allow us to answer that question.

Professor Mark Faghy
Professor of Clinical Exercise Science at Loughborough University and Visiting Professor at the University of Derby
The ERASE trial began in September 2024, around five years on from the start of the global COVID-19 pandemic, as part of a programme of research into the causes and impacts of Long Covid.
Seventy-three patients underwent a series of assessments at the University's specialist facilities, and at the University of Exeter, before receiving the antiviral drug intravenously for five consecutive days by clinical teams from University Hospitals of Derby and Burton NHS Foundation Trust (UHDB) and Royal Devon University Healthcare NHS Foundation Trust and in collaboration with Aston University.
The role of the PenCTU team was to ensure the feasibility study was managed correctly, that participants’ assessments and treatments were recorded appropriately, and that any data gathered in hospitals and by the research team was collected and processed in accordance with ethical and medical guidelines.
  • The full study – Faghy, M. et al.: An open-label feasibility study of remdesivir in Long COVID: Results from the ERASE LC trial – is published in Oxford Open Immunology, DOI: 10.1093/oxfimm/iqag014

University staff involved in this study